← Back to Clinical Trials
Recruiting NCT04599010

NCT04599010 Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04599010
Status Recruiting
Phase
Sponsor Nemours Children's Clinic
Condition Body Composition
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-09-26
Primary Completion 2027-07-31

Eligibility & Interventions

Sex All sexes
Min Age 1 Week
Max Age 10 Weeks
Study Type INTERVENTIONAL
Interventions
Dietary intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-09-26 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Large for Gestational Age (LGA) infants have excess fat-mass (FM) proportion secondary to prolonged in utero exposure to an energy-rich environment. Our preliminary data suggest that excess FM proportion can be associated with oral feeding delay and a potentially modifiable therapeutic target to improve oral feeding outcomes. The objective of this study is to determine the impact of a short-term Fat-free mass (FFM)-indexed feeding on the oral intake volumes in LGA infants with oral feeding difficulties.

Eligibility Criteria

Inclusion Criteria: * LGA infants with oral feeding difficulty born at ≥ 35 weeks gestation, with FM z-score \> +1.0 in body composition measurement Exclusion Criteria: * Infants on any respiratory support, Infants on enteral feeding duration \> 60 minutes due to hypoglycemia concerns, videofluoroscopic swallow study (VFSS) demonstrating unsafe swallowing function, GI surgical conditions, significant neurological morbidities, and major congenital, genetic syndromes/anomalies

Contact & Investigator

Central Contact

Sreekanth Viswanathan, MD,MS

✉ sreekanth.viswanathan@nemours.org

📞 4076977603

Principal Investigator

Sreekanth Viswanathan, MD

PRINCIPAL INVESTIGATOR

Nemours Children's Clinic

Frequently Asked Questions

Who can join the NCT04599010 clinical trial?

This trial is open to participants of all sexes, aged 1 Week or older, up to 10 Weeks, studying Body Composition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04599010 currently recruiting?

Yes, NCT04599010 is actively recruiting participants. Contact the research team at sreekanth.viswanathan@nemours.org for enrollment information.

Where is the NCT04599010 trial being conducted?

This trial is being conducted at Orlando, United States, Atlanta, United States.

Who is sponsoring the NCT04599010 clinical trial?

NCT04599010 is sponsored by Nemours Children's Clinic. The principal investigator is Sreekanth Viswanathan, MD at Nemours Children's Clinic. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology